Sumanirole
Template:Short description Template:Short description Page Template:Infobox drug/styles.css has no content.
Page Module:Infobox/styles.css has no content.
| Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found. | |
| Clinical data | |
|---|---|
| Other names | PNU-95,666 |
| ATC code | Page Template:Plainlist/styles.css has no content.
|
| Identifiers | |
| |
| CAS Number | Page Template:Plainlist/styles.css has no content. |
| PubChem CID | Page Template:Plainlist/styles.css has no content. |
| PubChem SID | Page Template:Plainlist/styles.css has no content. |
| IUPHAR/BPS | Page Template:Plainlist/styles.css has no content. |
| DrugBank | Page Template:Plainlist/styles.css has no content. |
| ChemSpider | Page Template:Plainlist/styles.css has no content. |
| UNII | Page Template:Plainlist/styles.css has no content. |
| KEGG | Page Template:Plainlist/styles.css has no content. |
| ChEBI | Page Template:Plainlist/styles.css has no content. |
| ChEMBL | Page Template:Plainlist/styles.css has no content. |
| NIAID ChemDB | Page Template:Plainlist/styles.css has no content. |
| PDB ligand | Page Template:Plainlist/styles.css has no content. |
| CompTox Dashboard (EPA) | Page Template:Plainlist/styles.css has no content. |
| Chemical and physical data | |
| Formula | C11H13N3O |
| Molar mass | 203.245 g·mol−1 |
| 3D model (JSmol) | Page Template:Plainlist/styles.css has no content. |
| |
| Data page | |
| Template:Infobox drug/data page link | |
Sumanirole (PNU-95,666) is a highly selective D2 receptor full agonist, the first of its kind to be discovered.[1][2][3] It was developed for the treatment of Parkinson's disease and restless leg syndrome. While it has never been approved for medical use[4][5] it is a highly valuable tool compound for basic research to identify neurobiological mechanisms that are based on a dopamine D2-linked (vs. D1-, D3-, D4-, and D5-linked) mechanism of action.[3]
In 2004, Pfizer announced the end of their clinical development program for sumanirole, citing “recent studies that failed to sufficiently distinguish sumanirole from currently available therapies”.[6]
See also
- List of investigational Parkinson's disease drugs
- List of investigational restless legs syndrome drugs
- Ropinirole
- PNU-91356A
References
Page Template:Reflist/styles.css has no content.
- ^ Romero AG, et al. Synthesis of the selective D2 receptor agonist PNU-95666E from D-phenylalanine using a sequential oxidative cyclization strategy. Journal of Organic Chemistry. 1997; 62(19):6582.
- ^ Page Module:Citation/CS1/styles.css has no content.McCall RB, Lookingland KJ, Bédard PJ, Huff RM (September 2005). "Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics. 314 (3): 1248–56. doi:10.1124/jpet.105.084202. PMID 15980060. S2CID 9835081.
- ^ a b Page Module:Citation/CS1/styles.css has no content.Weber M, Chang WL, Breier MR, Yang A, Millan MJ, Swerdlow NR (March 2010). "The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats". European Neuropsychopharmacology. 20 (6): 421–425. doi:10.1016/j.euroneuro.2010.02.011. PMC 2864324. PMID 20346635.
- ^ Page Module:Citation/CS1/styles.css has no content.Barone P, Lamb J, Ellis A, Clarke Z (March 2007). "Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease". Movement Disorders. 22 (4): 483–9. doi:10.1002/mds.21191. PMID 17115380. S2CID 20961008.
- ^ Page Module:Citation/CS1/styles.css has no content.Garcia-Borreguero D, Winkelman J, Adams A, Ellis A, Morris M, Lamb J, Layton G, Versavel M (March 2007). "Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study". Sleep Medicine. 8 (2): 119–27. doi:10.1016/j.sleep.2006.05.018. PMID 17239657.
- ^ Page Module:Citation/CS1/styles.css has no content.Pfizer, Inc. "Pfizer to Discontinue Sumanirole Development Program". Parkinson's Disease Foundation.
Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.
Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.